Download - Pickering.ppt
![Page 1: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/1.jpg)
Diagnostic Evaluation of the Hypertensive Patient-
How much is enough?
Thomas Pickering MD, DPhilBehavioral Cardiovascular Health and
Hypertension ProgramColumbia Presbyterian Medical Center
New York
![Page 2: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/2.jpg)
Diagnostic Evaluation of the Hypertensive Patient-
How much is enough?
• How high is the blood pressure?
• Why is it high?
• What is the risk?
![Page 3: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/3.jpg)
Diagnostic Evaluation of the Hypertensive Patient-
How much is enough?
• How high is the blood pressure?
How should it be measured?
![Page 4: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/4.jpg)
How should the Blood Pressure be Measured?
In the ClinicBy the doctor?By a nurse?By an automated device?
Outside the ClinicHome monitoring?Ambulatory monitoring?
![Page 5: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/5.jpg)
Ambulatory BP and Cardiovascular Disease in the Elderly with Systolic Hypertension:The Syst-Eur Study (N = 808)
Active treatment
60
50
40
30
20
10
0
190170150130110
Ca
rdio
va
scu
lar
dis
eas
e (p
er 1
000
pat
ien
t -
year
)
60
50
40
30
20
10
0
Placebo
DaytimeNighttime
24-hrClinic
190170150130110
Staessen et al. JAMA 1999; 282: 539-46.
High risk group- Clinic BP underestimates risk
Low risk group- WCH Clinic BP overestimates risk
![Page 6: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/6.jpg)
24 Hour Ambulatory Monitoring
![Page 7: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/7.jpg)
The White Coat Effect in the Real World(Little et al, BMJ 2002; 325: 254)
• 173 hypertensive patients in 3 general practices in the UK
• Clinic (MD and RN), self-monitoring, and ABPM
• White coat effect estimated as difference between other measures of BP and daytime BP:-
Physician 19/11 mmHg
Nurse 1 5/8 mmHg
Nurse 2 5/6 mmHg
Self-monitoring in clinic 10/13 mmHg
Self-monitoring at home 5/6 mmHg
![Page 8: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/8.jpg)
135/85 Ambulatory Pressure
140/90
Clinic Pressure Sustained
HypertensionWhite Coat Hypertension
True Normotension
Masked Hypertension
![Page 9: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/9.jpg)
• Measurement error
• Small number of readings
• Effects of recent activities
• Expense & Inconvenience
• White coat effect
A Diagnosis of Hypertension
based exclusively on Physician readings is no longer acceptable
![Page 10: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/10.jpg)
Prospective Studies Showing that Home BP Predicts CV Morbidity Better than Clinic BP
Author Year Population N Comments
Imai 1996 Population 1789 ABP & HBP predict, not CBP
Bobrie 2004 Treated 4939 HBP predicts, not CBP
Sega 2005 Population 2051 HBP predicts better than CBP
![Page 11: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/11.jpg)
Prospective Studies Showing that Home BP Predicts CV Morbidity Better than Clinic BP
Author Year Population N Comments
Imai 1996 Population 1789 ABP & HBP predict, not CBP
Bobrie 2004 Treated 4939 HBP predicts, not CBP
Sega 2005 Population 2051 HBP predicts better than CBP
![Page 12: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/12.jpg)
Call to Action for the Reimbursement of Home BP
Monitoring
Supported by
American Heart Association
American Society of Hypertension
Preventive Cardiovascular Nurses Association
![Page 13: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/13.jpg)
Which measure of Blood Pressure should we worry about most?
• Systolic?
• Diastolic?
• Pulse?
![Page 14: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/14.jpg)
Change of Blood Pressure with Age (NHANES- Black Women)
60
80
100
120
140
160
20 30 40 50 60 70
Blood Pressure
mm Hg
Age
Systolic
Diastolic
![Page 15: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/15.jpg)
Relations Between SBP, DBP and Stroke in Different Age Groups
(Prospective Studies Collaboration Lancet 2002; 360: 9349)
![Page 16: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/16.jpg)
Relations Between SBP, DBP and Stroke in Different Age Groups
(Prospective Studies Collaboration Lancet 2002; 360: 9349)
Even at ages 80-89 DBP risk
![Page 17: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/17.jpg)
0
20
40
60
80
100
<120 120-139 140-159 >160
<7070-74
75-7980-89
>100
Systolic Pressure (mm Hg)
Diastolic Pressure (mm Hg)
CHD Deaths Per
1000 Pt-Years
Neaton et al. Arch Intern Med. 1992;152;56.
CHD Deaths Versus SBP And DBP In MRFIT
![Page 18: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/18.jpg)
0
20
40
60
80
100
<120 120-139 140-159 >160
<7070-74
75-7980-89
>100
Systolic Pressure (mm Hg)
Diastolic Pressure (mm Hg)
CHD Deaths Per
1000 Pt-Years
Neaton et al. Arch Intern Med. 1992;152;56.
CHD Deaths Versus SBP And DBP In MRFIT
![Page 19: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/19.jpg)
Diagnostic Evaluation of the Hypertensive Patient-
How much is enough?
• How high is the blood pressure?
• Why is it high?
• What is the risk?
![Page 20: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/20.jpg)
JNC 7: Identifiable Causes of Hypertension
Sleep apnea Drug-induced or related causes Chronic kidney disease Primary aldosteronism Renovascular disease Chronic steroid therapy and Cushing’s syndrome Pheochromocytoma Coarctation of the aorta Thyroid or parathyroid disease
![Page 21: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/21.jpg)
JNC 7 Recommendations for Routine Work-up of Hypertensive Patients
Routine Tests• Electrocardiogram • Urinalysis • Blood glucose, and hematocrit • Serum potassium, creatinine, or the corresponding estimated GFR,
and calcium• Lipid profile, after 9- to 12-hour fast, that includes high-density and
low-density lipoprotein cholesterol, and triglycerides
Optional tests • Measurement of urinary albumin excretion or albumin/creatinine ratio
More extensive testing for identifiable causes is not generally indicated unless BP control is not achieved
![Page 22: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/22.jpg)
Dyslipidemia and the risk of Hypertension (Halperin et al Hypertens 2006: 47:45)
• 3110 men followed for 14 years in Physicians’ Health Study
• Baseline lipids analyzed by quintiles
LDL Chol HTN Risk by 39%
Tot Chol HTN Risk by 23%
HDL Chol HTN Risk by 32%Baseline
![Page 23: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/23.jpg)
Antihypertensive Effect of Pravastatin in Patients with Hypertension and Hypercholesterolemia (Glorioso et al; Hypertens 1999: 34:1281)
135
140
145
150
155
2
3
4
5
6
0 4 8 12 16 20 24 28 32 36 40 Weeks
Systolic pressure mmHg
LDL cholesterol mmol/l
Placebo Placebo
Placebo Statin
Statin Placebo
![Page 24: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/24.jpg)
ASCOT: Main Results (Blood Pressure-Lowering Arm: BPLA & Lipid-Lowering Arm: LLA)
Endpoint BPLA* LLA** Blood Pressure Lipids
Primary 10%- NS 36%
Death 11% 13%- NS
Stroke 23% 27%
Total events/ 16% 21% procedures
* BPLA- ACEI/CCB vs. BB/Diuretic
** LLA- Statin vs. placebo
Effects of intervention on events
![Page 25: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/25.jpg)
Cardiovascular Risk Factors in “Prehypertension” (TROPHY)
Two- 22%
None -4%
One- 14%Three or more- 59%
(Nesbitt et al, AJH 2005;18:980)
![Page 26: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/26.jpg)
Cardiovascular Risk Factors in “Prehypertension” (TROPHY)
Two- 22%
None -4%
One- 14%Three or more- 59% Cholesterol >200HDL <40TG >150BMI > 25Glucose >110Insulin >20Heart rate >80Hematocrit >43 or 41
(Nesbitt et al, AJH 2005;18:980)
![Page 27: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/27.jpg)
Overlap of Four Common Conditions
Sleep Sleep Disordered Disordered BreathingBreathing
HypertensionHypertension
ObesityObesity
DiabetesDiabetes
![Page 28: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/28.jpg)
Overlap of Four Common Conditions
Sleep Sleep Disordered Disordered BreathingBreathing
HypertensionHypertension
ObesityObesity
DiabetesDiabetes
![Page 29: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/29.jpg)
Association Between SDB and Hypertension- SHHS Parent Study
(Nieto et al, JAMA 2000;283,1829)
1
1.25
1.571.73
2.27
1 1.071.2 1.25
1.37
0.5
1
1.5
2
2.5
<1.5 1.5-4.9 5-14.9 15-29.9 >30
Odds Ratio of HTN
Apnea-Hypopnea Index per Hour
Adjusted for BMI etc.Not adjusted for BMI
![Page 30: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/30.jpg)
Sleep Disordered Breathing Predicts Hypertension- the Wisconsin Study
(Peppard et al, NEJM 2000; 342: 1378)
1.4
1.7
2.77
1
1.5
2
2.5
3
<5 5-14.9 >15
Apnea-Hypopnea Index
Odds Ratio for Hypertension*
*Adjusted for baseline BP, BMI, age etc.
![Page 31: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/31.jpg)
No Relationship between Isolated Systolic Hypertension & Sleep Apnea: SHHS Study
(Haas, Pickering et al, Circ 2005)
0
0.5
1
1.5
2
2.5S/D 40-59ISH 40-59ISH >60
<1.5 1.5-5 5-15 15-30 >30 AHI
Odds Ratio for HTN
P<0.002
NS
![Page 32: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/32.jpg)
Clinic BP140/90 mmHg
Awake ABP
135/85 mmHg
0
10
20
30
40
50
HighLow
High
Low
SHT
WCHT
MHT NT
%
% of SDBAHI > 15/hr
Prevalence of SDB in Hypertension
![Page 33: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/33.jpg)
Abnormalities Associated with the Metabolic Syndrome
Hypertension
Non-dipping pattern of 24 hr BP
Salt sensitive
Dyslipidemia
High triglycerides
Low HDL cholesterol
Increased small dense LDL
Insulin resistance
Type II diabetes
Increased NEFAs
Endothelial dysfunction
Increased PAI-I
Increased platelet aggregation
Microalbuminuria
Obstructive Sleep apnea
Central Obesity
![Page 34: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/34.jpg)
High Prevalence of Sleep Apnea in Resistant Hypertension
(Logan et al J Hypertens 2001:19:2271)
• 41 consecutive patients with 3 drug-resistant hypertension evaluated with PSG and ABPM
• Clinic BP was 168/94 on 3.6 drugs; most were obese • 83% had OSA (AHI >10); commoner in men (96%) than
women (65%)
• ABPM showed that 64% were non-dippers; no difference in dipping between those with and without OSA
![Page 35: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/35.jpg)
Situations in which Renin/Aldosterone Measurement
May Be Helpful
• Suspected secondary hypertension, e.g. hypokalemia (measure off drugs)
• Refractory hypertension (measure on drugs)
• Intolerance to multiple drugs (measure off drugs)
![Page 36: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/36.jpg)
Diagnostic Evaluation of the Hypertensive Patient-
How much is enough?
• How high is the blood pressure?
• Why is it high?
• What is the risk?
![Page 37: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/37.jpg)
JNC 7: CVD Risk Factors Hypertension* Cigarette smoking Obesity* (BMI >30 kg/m2) Physical inactivity Dyslipidemia* Diabetes mellitus* Microalbuminuria or estimated GFR <60 ml/min Age (older than 55 for men, 65 for women) Family history of premature CVD
(men under age 55 or women under age 65)*Components of the metabolic syndrome.
![Page 38: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/38.jpg)
JNC 7: Target Organ Damage
Heart• Left ventricular hypertrophy• Angina or prior myocardial infarction• Prior coronary revascularization• Heart failure
Brain• Stroke or transient ischemic attack
Chronic kidney disease
Peripheral arterial disease Retinopathy
![Page 39: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/39.jpg)
Why Is Echocardiography Useful In Hypertensive Patients?
“No other biological variable (except advancing age) predicts cardiac risk better
than left ventricular hypertrophy”.
(De Simone et al, J Hypertens 12;1129, 1994)
![Page 40: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/40.jpg)
How Common is LVH in Hypertensive Patients?
• ECG LVH in about 5% of ht patients
• Echo LVH in 15-30% of unselected ht patients• Echo LVH in 20 to 60% of ht patients in referral centers
![Page 41: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/41.jpg)
Indications for Echocardiography in Hypertensive Patients
• Coexistent Heart Disease
• Resistant Hypertension
• Decision to Start Treatment Uncertain
![Page 42: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/42.jpg)
Echocardiographic LVMI as a Predictor of CV Risk (Schillaci et al, Hypertens 2000; 35: 580)
0.85
1.66
2.24
2.86
4.34
0
1
2
3
4
5
1st 2nd 3rd 4th 5th
CV Events per 100-pt years
Quintiles of LVMI
![Page 43: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/43.jpg)
Microalbuminuria
Category Spot collection 24 hour g/mg creatinine mg/24 hr
Normal <30* <30
Microalbuminuria 30-300 30-300
Albuminuria >300 >300
Normal levels a bit lower in men (25 vs 35)
![Page 44: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/44.jpg)
Microalbuminuria Relation to other CV Risk Factors
• Hypertension
• Hyperlipidemia
• Central obesity
• Smoking
• LVH
• Coronary Disease
• Non-dipping BP pattern
![Page 45: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/45.jpg)
Urine Albumin Predicts CV and Non-CV Mortality in the General Population
(Hillege et al Circ 2002; 106: 1777)
0
1
2
3
4
5
6
10 100 1000
Hazard Ratio for Death
Urinary Albumin (mg/L)
Cardiovascular
Non-cardiovascular
![Page 46: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/46.jpg)
Microalbuminuria and CHD risk in Hypertension (Borch-Johnsen et al ATVB 1999;19:1992)
0
2
4
6
Nl
Hi
Systolic Pressure
Urine albumin
Relative risk of CHD
<140 140-160 >160 Low
High
![Page 47: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/47.jpg)
Effects of Enalapril and Nitrendipine on Urine Albumin (Bianchi et al AJH 1991; 4:291)
30
35
40
45
50
55
60
65
70
75
80
0 4 8 12 16
Urine albumin (mg/24 hr)
Enalapril
Nitrendipine
Weeks
![Page 48: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/48.jpg)
Diagnostic Evaluation of the Hypertensive Patient-
How much is enough?
In all patients
• Sleep history
• BMI
• Out-of-office Blood Pressures (home monitoring)
• Microalbuminuria
![Page 49: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/49.jpg)
Diagnostic Evaluation of the Hypertensive Patient-
How much is enough?
In selected patients
• Plasma renin/aldosterone
• Out-of-office Blood Pressures (ambulatory monitoring)
• Echocardiogram
![Page 50: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/50.jpg)
Seventh Report of the Joint National Committee onPrevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) EXPRESS
National Heart, Lung, andBlood Institute
National High Blood PressureEducation Program
![Page 51: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/51.jpg)
LVHSyst /DiastdysfunctionSilentischemia
SilentinfarctionDeep whitematterlesions
Micro-albuminuria
WallthickeningPlaque
CoronaryHeartDisease
CerebrovascularDisease
ChronicRenalFailure
PeripheralVascularDisease
Heart Brain Kidneys Arteries
Clinically Overt Target Organ Disease
Hypertension
Clinical Significance of Hypertensive Target Organ Damage
Silent Target Organ Damage
![Page 52: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/52.jpg)
Other Risk Factors & Grade 1 Grade 2 Grade 3
Disease History 140-159/90-99 160-179/100-109 >180/>110
I No other risk factors LOW RISK MED RISK HIGH RISK
II 1-2 risk factors MED RISK MED RISK V. HIGH RISK
III 3 or more risk factors HIGH RISK HIGH RISK V. HIGH RISK
IV ACC V. HIGH RISK V. HIGH RISK V. HIGH RISK
TOD or Diabetes
Blood Pressure mm Hg
Classification of Risk in Hypertension
![Page 53: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/53.jpg)
![Page 54: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/54.jpg)
Classification of Obesity by BMI
Obesity class BMI
Underweight <18.5
Normal 18.5-24.9
Overweight 25.0-29.9
Obesity grade I 30.0-34.9
II 35.0-39.9
Extreme obesity III >40
![Page 55: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/55.jpg)
Total & HDL Cholesterol as Predictors of ED
(Wei et al, Am J Epidemiol 1994;140:930)
• 3250 healthy men attending Cooper Clinic in Dallas• 71 developed new onset ED during a 2 year follow-up.
• Strongest predictors were total and HCDL cholesterol.
![Page 56: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/56.jpg)
The Massachussets Male Aging Study(Feldman et al, J Urol 151,54, 1994)
Predictors of ED
1. Disease• 39% with treated heart disease• 28% with treated diabetes• 15% with treated hypertension
(10% in general population)
![Page 57: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/57.jpg)
When to Suspect Sleep Apnea
![Page 58: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/58.jpg)
Predictors of Stroke and MI- PIUMA
Study (Verdecchia et al Circ 2001; 103; 2579)
Stroke Myocardial Infarction
Age Age
Gender Gender
Diabetes Diabetes
24-hr Mean BP 24-hr Pulse Pr
Cholesterol
Smoking
![Page 59: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/59.jpg)
Rationale- One Size Does Not Fit All
1. Level of risk varies greatly in hypertensive patients
2. Responsiveness to treatment varies greatly in hypertensive patients
![Page 60: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/60.jpg)
Rationale- One Size Does Not Fit All
1. Level of risk varies greatly in hypertensive patients
2. Responsiveness to treatment varies greatly in hypertensive patients
1. Need tests to improve prediction of risk in individual patients, e.g. ABPM, Echocardiography, microalbuminuria
![Page 61: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/61.jpg)
Rationale- One Size Does Not Fit All
1. Level of risk varies greatly in hypertensive patients
2. Responsiveness to treatment varies greatly in hypertensive patients
1. Need tests to improve prediction of risk in individual patients, e.g. ABPM, Echocardiography, microalbuminuria
2. Need tests to improve prediction of treatment response, e.g. renin
![Page 62: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/62.jpg)
Recommendations for Clinical Use of ABPM: JNC 7 & WHO-ISH
JNC 7 WHO-ISH
ABPM endorsed Yes Yes
Indications:
White Coat HTN Yes Yes
Labile BP Yes Yes
R/O hypotensive episodes Yes Yes
Resistant HTN Yes Yes
Autonomic dysfunction Yes No
![Page 63: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/63.jpg)
Ambulatory BP and Cardiovascular Disease in the Elderly with Systolic Hypertension:The Syst-Eur Study (N = 808)
Active treatment
60
50
40
30
20
10
0
190170150130110
Ca
rdio
va
scu
lar
dis
eas
e (p
er 1
000
pat
ien
t -
year
)
60
50
40
30
20
10
0
Placebo
DaytimeNighttime
24-hrClinic
190170150130110
Staessen et al. JAMA 1999; 282: 539-46.
![Page 64: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/64.jpg)
Ambulatory BP and Cardiovascular Disease in the Elderly with Systolic Hypertension:The Syst-Eur Study (N = 808)
Active treatment
60
50
40
30
20
10
0
190170150130110
Ca
rdio
va
scu
lar
dis
eas
e (p
er 1
000
pat
ien
t -
year
)
60
50
40
30
20
10
0
Placebo
DaytimeNighttime
24-hrClinic
190170150130110
Staessen et al. JAMA 1999; 282: 539-46.
High risk group- Clinic BP underestimates risk
![Page 65: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/65.jpg)
Two Types of Hypertension
1. Systolic and Diastolic Hypertension
- Younger and obese patients
- Evidence for increased sympathetic nerve activity
2. Isolated Systolic Hypertension
- Older and lean patients
- No evidence for increased sympathetic nerve activity
- Attributable to increased arterial stiffness
![Page 66: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/66.jpg)
Patient Evaluation
Evaluation of patients with documented HTN has three objectives:
1. Assess lifestyle and identify other CV risk factors or concomitant disorders that affects prognosis and guides treatment.
2. Reveal identifiable causes of high BP.
3. Assess the presence or absence of target organ damage and CVD.
![Page 67: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/67.jpg)
![Page 68: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/68.jpg)
Should Ambulatory Blood Pressure Monitoring, Echocardiogram, and Renin Determinations be Part of the Routine Evaluation of Hypertensive Patients?Conclusions- ABPM
• Many patients can be evaluated and treated by following the basic JNC 7 guidelines without ABPM
![Page 69: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/69.jpg)
Should Ambulatory Blood Pressure Monitoring, Echocardiogram, and Renin Determinations be Part of the Routine Evaluation of Hypertensive Patients?Conclusions- ABPM
• Many patients can be evaluated and treated by following the basic JNC 7 guidelines without ABPM
• Some type of out-of-office BP monitoring (home or ambulatory) is advisable in ALL patients
• ABPM is indicated when there is a discrepancy between either successive clinic readings or clinic and home readings
![Page 70: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/70.jpg)
Should Ambulatory Blood Pressure Monitoring, Echocardiogram, and Renin Determinations be Part of the Routine Evaluation of Hypertensive Patients?Conclusions- Echocardiography
• Many patients can be evaluated and treated by following the basic JNC 7 guidelines without echocardiography
![Page 71: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/71.jpg)
Should Ambulatory Blood Pressure Monitoring, Echocardiogram, and Renin Determinations be Part of the Routine Evaluation of Hypertensive Patients?Conclusions- Echocardiography
• Many patients can be evaluated and treated by following the basic JNC 7 guidelines without echocardiography
• Echocardiography is indicated if any of the following occur
– Coexistent heart disease
– Refractory hypertension
– Decision to treat uncertain
![Page 72: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/72.jpg)
Should Ambulatory Blood Pressure Monitoring, Echocardiogram, and Renin Determinations be Part of the Routine Evaluation of Hypertensive Patients?Conclusions-Renin measurement
• Many patients can be evaluated and treated by following the basic JNC 7 guidelines without renin measurement
![Page 73: Pickering.ppt](https://reader035.vdocuments.mx/reader035/viewer/2022062303/556e671bd8b42a6a248b4f1f/html5/thumbnails/73.jpg)
Should Ambulatory Blood Pressure Monitoring, Echocardiogram, and Renin Determinations be Part of the Routine Evaluation of Hypertensive Patients?Conclusions-Renin measurement
• Many patients can be evaluated and treated by following the basic JNC 7 guidelines without renin measurement
• Renin measurement is indicated in the following situations:
- Suspected secondary hypertension
- Refractory hypertension
- Intolerance to multiple drugs